Temat: leukemia - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Aktywna postawa lekarza versus inercja pacjenta: wykrycie przewlekłej białaczki szpikowej podczas badań okresowych
Active physician attitude vs. patient inertia: detection of chronic myeloid leukemia during periodic examinations
Autorzy:: Marcinkiewicz, Andrzej
Powiązania:: https://bibliotekanauki.pl/articles/2152951.pdf
Data publikacji:: 2022
Wydawca:: Instytut Medycyny Pracy im. prof. dra Jerzego Nofera w Łodzi
Tematy:: przewlekła białaczka szpikowa
wczesne wykrywanie
komunikacja lekarz–pacjent
stosowanie się do zaleceń lekarskich
udział pacjenta
zdrowie pracujących
chronic myeloid leukemia
early detection
physycian–patient communication
compliance
patient participation
occupational health
Opis:: Opis przypadku dotyczy zapoczątkowanego podczas badań okresowych postępowania profilaktyczno-orzeczniczego, które doprowadziło do wczesnego wykrycia przewlekłej białaczki szpikowej. Szczególną uwagę zwrócono na skrócenie terminu ważności badania okresowego uzasadnione nieprawidłowością w stanie zdrowia, która nie miała bezpośredniego związku z warunkami zawodowymi, oraz na sposób komunikacji i wpływ na pracownika, aby zastosował się do zaleceń lekarskich. Wywnioskowano, że wprawdzie obligatoryjne i cykliczne badania profilaktyczne do celów Kodeksu pracy stwarzają możliwość wczesnego wykrycia nieuświadomionych stanów chorobowych, dając tym samym szansę na poprawę stanu zdrowia pacjentów, ale jednocześnie mogą być traktowane jako ingerencja w prawo do samostanowienia jednostki o własnym życiu i zdrowiu. Uznano, że w ocenie sytuacji kluczowe są postawa lekarza medycyny pracy oraz sposób komunikacji z badanym pracownikiem, które nie tyle zmuszą, ile przekonają – dla dobra pacjenta – do podjęcia diagnostyki lub interwencji prozdrowotnej.
The case report concerns the prophylactic and medical certification procedure initiated during periodic examinations, which led to the early detection of chronic myeloid leukemia. Particular attention was paid to the shortening of the period of validity of the periodic examination, justified by an abnormal health condition that is not directly related to the working conditions, as well as the method of communication and influencing the employee to comply with medical recommendations. The conclusions stated that, although obligatory and periodic preventive examinations for the purposes of the Labor Code create the possibility of early detection of unawereness of disease, thus giving a chance to improve health, but at the same time they can be treated as an interference with the individual’s right to self-determination about his life and health. It was noted that the key factor in assessing the situation would be the attitude of the occupational medicine physician and the manner of his communication with the employee, who would not be forced, but convinced – for his benefit, to undertake diagnostics or health interventions.
Źródło:: Medycyna Pracy; 2022, 73, 6; 485-490
0465-5893
2353-1339
Pojawia się w:: Medycyna Pracy
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: ANALYSIS OF CHRONIC MYELOID LEUKEMIA PHARMACOTHERAPY COSTS IN POLAND
Autorzy:: Paczkowska, Anna
Kus, Krzysztof
Nowicka, Monika
Kopciuch, Dorota
Zaprutko, Tomasz
Komarnicki, Mieczysław
Nowakowska, Elżbieta
Powiązania:: https://bibliotekanauki.pl/articles/895298.pdf
Data publikacji:: 2019-02-28
Wydawca:: Polskie Towarzystwo Farmaceutyczne
Tematy:: poland
chronic myeloid leukemia
stem cell transplantation
pharmacotherapy cost analysis
Opis:: The aim of this study was to analyze pharmacotherapy cost of chronic myeloid leukemia from the society’s, the payer’s (National Health Fund), and the patient’s perspective. The study included 55 patients with a diagnosed and treated chronic myeloid leukemia at the selected hematology clinic in the city of Poznan. Retrospective study involved time horizon of one calendar year – 2013. The data required for economic evaluation were obtained from the patients’ case histories and the Department of Organization and Accounting of the selected health care facilities. The total cost of chronic myeloid leukemia pharmacotherapy for 55 patients from the society’s perspective in 2013 amounted to 1,483,416.88 EUR. Average annual cost of medication per patient in 2013 amounted to 26,971.22 EUR (Median – 32,854.22 EUR). Average cost of chronic myeloid leukemia pharmacotherapy for a patient without transplantation was 32,167.34 EUR (Median – 30,623.00 EUR), and for a patient after transplantation amounted to 413.13 EUR (Median – 378.40 EUR). The cost from the payer’s perspective is 99.93% of total costs from the society’s perspective. The cost from the patient’s perspective represents 0.07% of the total cost of chronic myeloid leukemia pharmacotherapy from the society’s perspective. Costs of chronic myeloid leukemia pharmacotherapy are very high and represent a significant burden to society. The highest costs associated with treatment of chronic myeloid leukemia are incurred by the society, and, subsequently, the public payer (NHF), and the patient.
Źródło:: Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 1; 175-183
0001-6837
2353-5288
Pojawia się w:: Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 3.

Tytuł:: Analysis of dose distribution around a computed tomography scanner in terms of exposure to scattered ionizing radiation of caregivers of pediatric patients
Autorzy:: Biegała, Michał
Brodecki, Marcin
Skoczylas, Krystian
Jakubowska, Teresa
Domienik-Andrzejewska, Joanna
Powiązania:: https://bibliotekanauki.pl/articles/45912311.pdf
Data publikacji:: 2024-09-10
Wydawca:: Instytut Medycyny Pracy im. prof. dra Jerzego Nofera w Łodzi
Tematy:: effective dose
radiological protection
leukemia
CT scanner
probability of induction of leukemia
pediatric radiology
Opis:: Objectives During computed tomography (CT), a large amount of ionizing radiation is emitted to ensure high quality of the obtained radiological image. This study measured the dose distribution around the CT scanner and the exposure of people staying near the CT scanner during the examination. Material and Methods The measurements used an anthropomorphic phantom to assess human exposure to ionizing radiation. The probability of inducing leukemia and other cancers as a result of absorbing doses recorded around the CT device was also calculated. Results The highest exposure to scattered radiation in the proximity of the CT scanner is recorded at the gantry of the tomograph, i.e., 55.7 μGy, and the lowest, below lower detection limit of 6 μGy at the end of the diagnostic table. The whole-body detector placed on the anthropomorphic phantom located at the diagnostic table right next to the CT gantry recorded 59.5 μSv and at the end of the table 1.5 μSv. The average doses to the lenses in these locations were: 32.1 μSv and 2.9 μSv, respectively. Conclusions The probability of induction of leukemia or other types of cancer is low, but the need for people to stay in the examination room during a CT examination should be limited to the necessary minimum.
Źródło:: International Journal of Occupational Medicine and Environmental Health; 2024, 37, 3; 326-334
1232-1087
1896-494X
Pojawia się w:: International Journal of Occupational Medicine and Environmental Health
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 4.

Tytuł:: Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin - prelimary results
Autorzy:: Wasik-Szczepanek, E.
Szymczyk, A.
Kowal, M.
Nogalski, A.
Hus, M.
Powiązania:: https://bibliotekanauki.pl/articles/2081565.pdf
Data publikacji:: 2018
Wydawca:: Instytut Medycyny Wsi
Tematy:: chronic lymphocytic leukemia
ofatumumab
monoclonal antibodies
immunotherapy
Opis:: Introduction. Despite significant recent advances in the treatment of chronic lymphocytic leukaemia (CLL), most cases of the disease are still incurable. Treatment with monoclonal antibodies, such as ofatumumab, is one of the new therapeutic options. Objective. Retrospective analysis of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia (CLL) treated in the Haematooncology and Bone Marrow Transplantation Department of the Medical University of Lublin, Poland, during 2011–2013. Materials and method. The analysis included 5 patients (3 women and 2 men), aged 47–65, with Rai stage II-IV CLL, after a few lines of treatment. Three patients received ofatumumab in monotherapy and 2 patients received ofatumumab in combination with cyclophosphamide (50 mg/day) and dexamethasone (40 mg/day). All patients included in the study were diagnosed with an active form of leukaemia with symptoms such as lymphocytosis or massive lymphadenopathy. Results. All patients responded to the treatment. Within the first 8 weeks of the treatment, levels of white blood cells returned to normal in patients with baseline lymphocytosis (3 patients). An increase in platelet levels was reported in 3 patients. Haemoglobin levels were higher or comparable to the baseline values in all studied patients after the completion of immunotherapy. In the patient with massive lymphadenopathy and hepato- and splenomegaly, the size of the lymph nodes, spleen and liver decreased and neutrophil levels increased. Time of progression was 5–12 months, and in one patient partial remission has been maintained. The treatment was well-tolerated in most cases. Asymptomatic neutropenia and an infection with Candida glabrata were observed. Conclusions. Ofatumumab may be a new and safe therapeutic option for patients with CLL after a few lines of treatment.
Źródło:: Annals of Agricultural and Environmental Medicine; 2018, 25, 1; 56-59
1232-1966
Pojawia się w:: Annals of Agricultural and Environmental Medicine
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 5.

Tytuł:: CD40 stimulation induces differentiation of acute lymphoblastic leukemia cells into dendritic cells
Autorzy:: Łuczyński, Włodzimierz
Stasiak-Barmuta, Anna
Iłendo, Elżbieta
Krawczuk-Rybak, Maryna
Malinowska, Iwona
Mitura-Lesiuk, Małgorzata
Parfieńczyk, Adam
Szymański, Marcin
Powiązania:: https://bibliotekanauki.pl/articles/1041252.pdf
Data publikacji:: 2006
Wydawca:: Polskie Towarzystwo Biochemiczne
Tematy:: immunotherapy
T-lymphocytes
CD40L
acute lymphoblastic leukemia
dendritic cells
Opis:: Despite the very high percentage of long-term remissions in acute lymphoblastic leukemia (ALL) in children, some of them suffer from recurrence of the disease. New treatment modalities, e.g. effective geno- and immunotherapy are needed. The use of neoplasmatic cells to present tumor antigens is one of the approaches in cancer vaccines. ALL cells lack the expression of costimulatory molecules and are poor antigen presenting cells (APCs) for T-cell activation. CD40/40L interaction stimulates B-cells to proliferate, differentiate, upregulate costimulatory molecules and increase antigen presentation. The aim of the study was to test the hypothesis that ALL cells can be turned into professional APCs by CD40L activation. Children with B-cell precursor ALL were enrolled into the study. Mononuclear cells from bone marrow or peripheral blood were stimulated with CD40L and interleukin 4. Results: 1) after culture we noted upregulation of all assessed costimulatory, adhesion and activatory molecules i.e. CD1a, CD11c, CD40, CD54, CD80, CD83, CD86, CD123, HLA class I and II; 2) CD40L activated ALL cells induced proliferation of allogeneic T-cells (measured by [3H]thymidine incorporation). These results confirm the possibility of enhancing the immunogenicity of ALL cells with the CD40L system and indicate that this approach can be used in immunotherapeutic trials.
Źródło:: Acta Biochimica Polonica; 2006, 53, 2; 377-382
0001-527X
Pojawia się w:: Acta Biochimica Polonica
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 6.

Tytuł:: Charakterystyka elektroforetyczna aktywności metaloproteinazowej surowicy pacjentów z przewlekłą białaczką limfocytową – badania wstępne
Electrophoretic characteristics of metalloproteinase’s activity of serum of patients with chronic lymphocytic leukemia – preliminary data
Autorzy:: Pietrzak, Jan
Wodziński, Damian
Franiak-Pietryga, Ida
Mirowski, Marek
Powiązania:: https://bibliotekanauki.pl/articles/1032615.pdf
Data publikacji:: 2015
Wydawca:: Łódzkie Towarzystwo Naukowe
Tematy:: metaloproteinazy
żelatynazy
przewlekła białaczka
limfocytowa
zymografia
mmp–9
mmp–2
metalloproteinases
gelatinases
chronic lymphatic leukemia
zymography
Opis:: Metalloproteinases play an important role in the development and metastasis of many cancers. Their activity is also an important component of tumorgenesis associated processes such as angiogenesis, decreased apoptosis, or unlimited proliferation of pathological cells. In this study we tried to estimate a differences of metalloproteinase activity digesting the gelatin in the sera of patients with chronic lymphocytic leukemia and healthy people, by the zymographic technique. To confirm that the gelatinolytic activity originated from the metalloproteinases their specific inhibitors: phenanthroline and ethylene– diaminetetraacetic acid were used. In patient’s sera a zymographic analysis revealed the presence of additional activity. The first of them are located in a region corresponding to a molecular weight of approximately 240 kDa, probably corresponds to the dimer of proMMP–9. Another two active fractions present in the sera of patients suffering from leukemia corresponded to a molecular weight of about 110 and 130 kDa probably represents a complex of proMMP–9 with lipocain. In a control sera, only one activity could be observed exhibiting a molecular weight of about 110 kDa, which is stronger than corresponding fraction in patient’s sera. The biggest difference between the two investigated sera was gelatynolytic activity located in the region of a molecular weight of about 94 kDa, which probably corresponded to proMMP–9. In some leukemic sera this activity was several times higher compared to the control samples, in which there was a constant and relatively low level of it. Despite significant activity of proMMP–9 in sera of patients with CLL no biologically active equivalent band of molecular weight 84 kDa were detected. The fractions which corresponded to different forms of MMP–2 (72, 64 kDa) were present in the sera of tumor and control, although proMMP–2 was more strongly expressed in the control samples.
Źródło:: Folia Medica Lodziensia; 2015, 42, 1; 49-62
0071-6731
Pojawia się w:: Folia Medica Lodziensia
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 7.

Tytuł:: Chemioterapia w ciąży
Chemotherapy during pregnancy
Autorzy:: Sznurkowski, Jacek J.
Klasa-Mazurkiewicz, Dagmara
Kobierski, Juliusz
Wydra, Dariusz
Emerich, Janusz
Powiązania:: https://bibliotekanauki.pl/articles/1030942.pdf
Data publikacji:: 2010
Wydawca:: Medical Communications
Tematy:: cervical cancer
chemotherapy
pregnancy breast cancer
leukemia
białaczka
chemioterapia
ciąża
rak piersi
rak szyjki macicy
Opis:: Chemotherapy in the treatment of malignant tumors in pregnant women potentially threatens life and development of the fetus. Aim of paper: The purpose of this paper was to update current knowledge concerning the role of chemotherapy in combination therapy of gynecologic malignancies complicating pregnancy and to review available literature focusing on potential sequels of administration of chemotherapeutics at different time-points in pregnancy, with particular emphasis on fetal development, course of pregnancy and future lot of the child. Method: The PubMed database was searched using the following key words: methotrexate; 5-fluorouracil; aminopterin; thioguanine; mercaptopurine; cyclophosphamide; busulfan; ifosfamide; chlorambucil; dacarbazine; doxorubicin; daunorubicin; adriamycin; idarubicin; epirubicin; dactinomycin; bleomycin; mitoxantrone; vincristine; vinblastine; vinorelbine; paclitaxel; docetaxel; cisplatin; carboplatin; prednisone; tamoxifen; etoposide; teniposide; allopurinol; malformation; IUGR; chemotherapy; pregnancy. Search criteria were fulfilled by 33 papers (selected chemotherapeutic agent/pregnancy/malformation), which subsequently underwent content-related analysis. Conclusions: A decision on the use of chemotherapy during pregnancy should be made depending on type and stage of malignancy. It at all possible, administration of cytostatics should be delayed until the end of first trimester. If the patient requires multidrug therapy in the first trimester, she should receive anthracycline-derived antibiotics combined with Vinca alkaloids or should be placed on monotherapy and after 12 weeks shift to a multidrug regimen. Delivery should be planned for the 35th gestational week and 2-3 weeks after termination of chemotherapy in order to allow recovery of bone-marrow function.
Chemioterapia w leczeniu nowotworów złośliwych u kobiet w ciąży stanowi potencjalne zagrożenie dla życia i rozwoju płodu. Celem pracy było przybliżenie wiedzy na temat udziału chemioterapii w leczeniu skojarzonym nowotworów ginekologicznych wikłających ciążę oraz dokonanie przeglądu doniesień medycznych pod kątem skutków zastosowania poszczególnych czynników chemioterapeutycznych w różnych trymestrach ciąży, ze szczególnym uwzględnieniem wpływu na rozwój płodu, przebieg ciąży i dalsze losy dziecka. Metoda: Przy użyciu słów kluczowych: methotrexate; 5-fluorouracil; aminopterin; thioguanine; mercaptopurine; cyclophosphamide; busulfan; ifosfamide; chlorambucil; dacarbazine; doxorubicin; daunorubicin; adriamycin; idarubicin; epirubicin; dactinomycin; bleomycin; mitoxantrone; vincristine; vinblastine; vinorelbine; paclitaxel; docetaxel; cisplatin; carboplatin; prednisone; tamoxifen; etoposide; teniposide; allopurinol; malformation; IUGR; chemotherapy; pregnancy przeszukano bazę PubMed. Odnaleziono 33 artykuły anglojęzyczne spełniające kryteria wyszukiwania (wybrany czynnik chemioterapeutyczny/ciąża/malformacja), które poddano analizie merytorycznej. Wnioski: Decyzję o chemioterapii w ciąży należy podjąć stosownie do rodzaju nowotworu i jego stopnia zaawansowania klinicznego. Jeśli jest to tylko możliwe, należy odroczyć podawanie cytostatyków do końca pierwszego trymestru. W sytuacji, w której pacjentka wymaga terapii wielolekowej w pierwszym trymestrze, należy rozważyć zastosowanie antybiotyków antracyklinowych w połączeniu z alkaloidami Vinca lub rozpocząć leczenie terapią jednolekową i po 12 tygodniach przejść na schemat wielolekowy. Poród powinien być zaplanowany na 2 do 3 tygodni po zakończeniu chemioterapii, w celu umożliwienia powrotu prawidłowej czynności szpiku (około 35. tygodnia).
Źródło:: Current Gynecologic Oncology; 2010, 8, 2; 123-131
2451-0750
Pojawia się w:: Current Gynecologic Oncology
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 8.

Tytuł:: Comparison of the WHO classification (5th edition) 2022 and the International Consensus Classification (ICC) 2022 for diagnosis of acute myeloid leukemia
Autorzy:: Al-Nakkash, Naba
Frenzel, Lukas P.
Powiązania:: https://bibliotekanauki.pl/articles/35505928.pdf
Data publikacji:: 2024
Wydawca:: Radomskie Towarzystwo Naukowe
Tematy:: AML
WHO
ICC
acute myeloid leukemia
World Health Organisation
International Consensus Classification
ostra białaczka szpikowa
Światowa Organizacja Zdrowia
Opis:: In 2022, two classifications were published to define the diagnosis of patients with acute myeloid leukemia (AML). The World Health Organisation (WHO) 5th edition and the International Consensus Classification (ICC) provide an updated summary of current knowledge of the diseases and construct a framework for physicians. Two differing classifications result in discrepancies, which change the definition of AML subtypes and present a challenge in clinical settings. This work summarizes the updated classification systems and discusses their significance in clinical settings while considering the latest findings. Relevant changes affect the i) required blast percentage, ii) AML harbouring CEBPA mutations, iii) AML with KMT2A and MECOM rearrangements, iv) AML with myelodysplasia-related characteristics and in association with this entity AML with mutated RUNX1, and lastly v) AML with TP53 mutation. In summary, a unified classification system would be desirable to achieve harmonized diagnosis and treatment of AML).
Źródło:: Scientiae Radices; 2024, 3, 1; 14-29
2956-4808
Pojawia się w:: Scientiae Radices
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 9.

Tytuł:: Cross-resistance to five glucocorticoids in childhood acute lymphoblastic and non-lymphoblastic leukemia samples tested by the MTT assay: Preliminary report.
Autorzy:: Styczyński, Jan
Wysocki, Mariusz
Dębski, Robert
Balwierz, Walentyna
Rokicka-Milewska, Roma
Matysiak, Michał
Balcerska, Anna
Kowalczyk, Jerzy
Wachowiak, Jacek
Sońta-Jakimczyk, Danuta
Chybicka, Alicja
Powiązania:: https://bibliotekanauki.pl/articles/1043813.pdf
Data publikacji:: 2002
Wydawca:: Polskie Towarzystwo Biochemiczne
Tematy:: cross-resistance
ALL
sensitivity
acute leukemia
MTT assay
AML
glucocorticoid resistance
Opis:: In vitro antileukemic activity of five glucocorticoids and their cross-resistance pattern in childhood acute lymphoblastic and non-lymphoblastic leukemia were determined by means of the MTT assay in 25 leukemia cell samples of childhood acute leukemias. The equivalent antileukemic concentrations of the drugs tested were: 34 μM hydrocortisone (HC), 8 μM prednisolone (PRE), 1.5 μM methylprednisolone (MPR), 0.44 μM dexamethasone (DX) and 0.22 μM betamethasone (BET). In comparison with initial ALL cell samples, the relapsed ALL group was more resistant to PRE (38-fold, p = 0.044), DX (> 34-fold, p = 0.04), MPR (38-fold), BET (45-fold) and HC (33-fold). The AML cell samples were even more resistant to: PRE (>85-fold, p=0.001), DX (> 34-fold, p = 0.004), MPR (> 69-fold, p = 0.036), BET (> 69-fold, p = 0.038) and HC (54-fold, p = 0.059) when compared with ALL on initial diagnosis. A significant cross-resistance among all the glucocorticoids used was found. Only in some individual cases the cross-resistance was less pronounced.
Źródło:: Acta Biochimica Polonica; 2002, 49, 1; 93-98
0001-527X
Pojawia się w:: Acta Biochimica Polonica
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 10.

Tytuł:: Cytotoxic effect of nitric oxide on human hematological malignant cells.
Autorzy:: Tsumori, Michihiro
Tanaka, Junko
Koshimura, Kunio
Kawaguchi, Mikiko
Murakami, Yoshio
Kato, Yuzuru
Powiązania:: https://bibliotekanauki.pl/articles/1043819.pdf
Data publikacji:: 2002
Wydawca:: Polskie Towarzystwo Biochemiczne
Tematy:: lymphoma
myeloma
leukemia
nitric oxide
Opis:: We investigated the cytotoxic effect of nitric oxide (NO) on primary culture of human hematological malignant cells. Sodium nitroprusside (SNP), an NO donor, had cytotoxic effects on the cells of some patients with malignant lymphoma (ML), acute myelocytic leukemia (AML) or chronic myelomonocytic leukemia (CMMoL), but not with multiple myeloma. Cultured cells from the ML patient remained sensitive to SNP after the cells became resistant to anti-cancer drugs. In contrast, the cells from the patients with AML and CMMoL became resistant to SNP while anti-cancer drugs remained effective. In samples of the cells of the patients with ML and AML, the number of CD3 positive lymphoma cell was decreased by SNP and the number of CD33 negative cells and normal B lymphocytes (CD19 positive cells) were increased. In the cells of the patient with ML, apoptosis was induced by SNP. SNP had no effect on lymphocytes of healthy volunteers. These results suggest that SNP had an anti-tumor effect on human hematological malignant cells.
Źródło:: Acta Biochimica Polonica; 2002, 49, 1; 139-144
0001-527X
Pojawia się w:: Acta Biochimica Polonica
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 11.

Tytuł:: Cytotoxic effects of cladribine and tezacitabine toward HL-60.
Autorzy:: Stachnik, Krzysztof
Grieb, Paweł
Skierski, Janusz
Powiązania:: https://bibliotekanauki.pl/articles/1041452.pdf
Data publikacji:: 2005
Wydawca:: Polskie Towarzystwo Biochemiczne
Tematy:: tezacitabine
cladribine
flow cytometry
nucleoside analogs
leukemia
HL-60 cells
Opis:: The aim of the study was to determine the relation between the cytotoxic and cytostatic effects of tezacitabine and cladribine on a HL-60 cell line and the time of exposure of cells to these drugs. Cell viability and induction of apoptosis were assessed using flow cytometry methods. Apoptosis was confirmed by direct microscopic observation. Growth inhibition was examined by cell counting. After 24 h incubation tezacitabine was equally or less toxic compared to cladribine. However, toxicity of tezacitabine strongly rose after 48 h incubation leading to massive cell death at doses much lower than those of cladribine. Assessment of the effect of increased exposure time on the clinical efficacy of tezacitabine is indicated.
Źródło:: Acta Biochimica Polonica; 2005, 52, 2; 561-565
0001-527X
Pojawia się w:: Acta Biochimica Polonica
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 12.

Tytuł:: Cytotoxic, Genotoxic and Apoptotic Activity of Isolated Compound from Pandanus odorattissimus
Autorzy:: Kamble, Abhaykumar
Swamy, Paramjyothi
Powiązania:: https://bibliotekanauki.pl/articles/1161866.pdf
Data publikacji:: 2018
Wydawca:: Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Tematy:: Apoptotic activity
Comet assay
Cytotoxic activity
Human Leukemia 60 (HL-60) cells
Pandanus odorattissimus L
Opis:: The present study reports potential activities like cytotoxic, genotoxic and apoptotic activity of phenolic compound 4-(4-(3,4-dimethoxyphenyl)hexahydrofuro[3,4-c]furan-1-yl)-2-methoxyphenyl acetate isolated from methanolic extract of Pandanus odorattissimus. The compound showed a signiﬁcant cytotoxic effect on Human Leukemia 60 (HL-60) cell line. Exposure of the compound reduced the viability of HL-60 cells after 12, 24 and 48 hours, the compound exerted a significant cytotoxic effect on HL-60 cells. The compound also induced significant DNA damage. The results of comet assay with pattern of the HL-60 cells has shown an intact head and complete absence of DNA fragments in the form of tail suggesting that the doses are not genototoxic. The phenolic compound at concentration of 20 µg/mL, showed an increase in percentage tail of DNA upto 6.21 units when compared to control 5.35. Although all of the compound induced significant DNA damage it induced apoptotic in the middle level and led to significant level. Apoptotic effect of compound on HL-60 cells after 72 h increased. Furthermore, the compound induced slight necrosis in HL-60 cells. Although the compound induced significant DNA damage, it induced apoptotic at the middle level. Apoptotic effect of compound on HL cells after 72 hrs increased level, furthermore the compound induced slight necrosis in HL-60 cells.
Źródło:: World Scientific News; 2018, 112; 193-206
2392-2192
Pojawia się w:: World Scientific News
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 13.

Tytuł:: Czy galusan epigallokatechiny może być skutecznym polifenolem w terapii skojarzonej z etopozydem w leczeniu przewlekłej białaczki szpikowej?
Can epigallocatechin gallate be an effective polyphenol in combination therapy with etoposide for the treatment of chronic myelogenous leukemia?
Autorzy:: Cierniak, Agnieszka
Skubal, Magdalena
Kalemba-Drożdż, Małgorzata
Powiązania:: https://bibliotekanauki.pl/articles/970179.pdf
Data publikacji:: 2018
Wydawca:: Krakowska Akademia im. Andrzeja Frycza Modrzewskiego
Tematy:: apoptoza
EGCG
etopozyd
przewlekła białaczka szpikowa
uszkodzenia DNA
apoptosis
etoposide
chronic myeloid leukemia
DNA damage
Opis:: Wprowadzenie: Składnik zielonej herbaty – galusan epigallokatechiny (EGCG) – znany jest ze swoich właściwości chemoprewencyjnych i chemoterapeutycznych. Wykazuje silne właściwości antyoksydacyjne i przeciwzapalne, a w stosunku do komórek nowotworowych – działanie antyproliferacyjne lub proapoptotyczne. Etopozyd jest jednym z najczęściej stosowanych leków przeciwnowotworowych, wywołującym jednak wiele skutków ubocznych. Materiały i metody: W eksperymentach in vitro badano potencjalną rolę EGCG w terapii skojarzonej z etopozydem w leczeniu przewlekłej białaczki szpikowej. Komórki ustalonej linii białaczkowej K562 poddano działaniu etopozydu i/lub EGCG w celu określenia wpływu EGCG na przeżywalność komórek, poziom uszkodzeń DNA oraz częstość procesu apoptozy. Poziom uszkodzeń DNA mierzono przy pomocy elektroforezy pojedynczych komórek w żelu agarozowym (test kometowy), natomiast apoptozę oceniano pod mikroskopem fluorescencyjnym z użyciem barwnika Hoechst 33342. Wyniki: Uzyskane wyniki badań wskazują, że EGCG w stężeniu 50 i 100 μM uwrażliwia komórki białaczkowe na cytotoksyczne działanie etopozydu, zwiększając poziom uszkodzeń DNA i częstość apoptozy. Wnioski: Dane wskazują, że galusan epigallokatechiny może się okazać skutecznym polifenolem w terapii skojarzonej z etopozydem w leczeniu przewlekłej białaczki szpikowej
Introduction: Green tea ingredient – epigallocatechin gallate (EGCG) – is known for its chemopreventive and chemotherapeutic properties. It has strong antioxidant and anti-inflammatory properties, and antiproliferative or pro-apoptotic activity against cancer cells. Etoposide is one of the most commonly used anti-cancer drugs causing many side effects. Materials and methods: This study investigated the role of EGCG in combination therapy with etoposide in the treatment of chronic myeloid leukemia. K562 cells were treated with EGCG and / or etoposide to determine the effect of this polyphenol on cell survival, DNA damage or apoptosis. DNA damages were measured with single cell gel electrophoresis (comet assay) and the apoptosis were analyzed in fluorescence microscope with Hoechst 33342 staining. Results: Preliminary results suggest that EGCG at 50 and 100 μM sensitizes leukemic cells to the cytotoxic effect of etoposide, increases DNA damage that promotes removal cell and directs them to apoptosis. Conclusions: The data show that epigallocatechin gallate may prove to be an effective polyphenol in combination therapy with etoposide in the treatment of chronic myeloid leukemia. However, further research is needed to explain the EGCG interaction with chemotherapeutics.
Źródło:: Państwo i Społeczeństwo; 2018, 3; 9-28
1643-8299
2451-0858
Pojawia się w:: Państwo i Społeczeństwo
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 14.

Tytuł:: Deep molecular response (MR4.5) as a target of therapy with tyrosine kinase inhibitors. MR4.5 – goal of CML treatment
Autorzy:: Sacha, Tomasz
Powiązania:: https://bibliotekanauki.pl/articles/1065835.pdf
Data publikacji:: 2014
Wydawca:: Medical Education
Tematy:: chronic myeloid leukemia
possibility cure
therapy targets
tyrosine kinase inhibitors
Opis:: Chronic myeloid leukemia (CML) accounts for 15% of diagnosed leukemias. The annual incidence in two Polish regions has been calculated for 0.7/100,000 of general population. Introduction of tyrosine kinase inhibitors (TKIs) have substantially improved not only the prognosis of CML, but also changed the treatment goals, and the expectations of patients and physicians. The goals of CML therapy include: to prevent the progression towards accelerated phase and blastic phase, to eliminate the risk of death from leukemia, to prolong the length of survival to comparable of healthy population and to attain a quality of life comparable to healthy people. Patients treated up-front with second generation TKIs (2GTKI) have a better chance to achieve faster and deeper response to therapy. Most of patients receiving 2GTKI in first line or e.g. nilotinib after initial phase of imatinib therapy can achieve very deep molecular response (MR4.5), which is a key criterion for discontinuation studies. The results of stop-trials suggest that substantial proportion of patient could achieve sustained treatment-free survival, and that the disease could be controlled despite of persistence of minimal residual disease, which does not require a clinical intervention. Patients group that could benefit most from discontinuation study include younger people, those who have achieved MR4.5 and patients reporting TKI – associated side effects. Achievement of MR4.5 could be considered as a target of CML therapy for considerable proportion of patients. The question of safe TKI dose reduction or therapy cessation should be addressed in the future planned clinical trials.
Źródło:: OncoReview; 2014, 4, 1; A27-32
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki